Notably, RANKL has been implicated in the pathogenesis of myeloma bone disease, in addition to that of breast and prostate cancer, although anti-RANKL is currently only approved for the treatment of solid tumor metastases [8]. Here, TNFSF11 is linked to Familial prostate cancer.